Tumor Suppressor Function of Syk in Human MCF10A In Vitro and Normal Mouse Mammary Epithelium In Vivo

被引:35
作者
Sung, You Me
Xu, Xuehua
Sun, Junfeng
Mueller, Duane
Sentissi, Kinza
Johnson, Peter
Urbach, Elana
Seillier-Moiseiwitsch, Francoise
Johnson, Michael D.
Mueller, Susette C.
机构
[1] Department of Oncology, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
[2] Department of Biostatistics Bioinformatics and Biomathematics, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, Washington, DC
关键词
BREAST-CANCER CELLS; PROTEIN-TYROSINE KINASE; MESENCHYMAL TRANSITION; INVADOPODIA FORMATION; MATRIX DEGRADATION; CARCINOMA CELLS; KAPPA-B; VIMENTIN; GROWTH; MODEL;
D O I
10.1371/journal.pone.0007445
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
The normal function of Syk in epithelium of the developing or adult breast is not known, however, Syk suppresses tumor growth, invasion, and metastasis in breast cancer cells. Here, we demonstrate that in the mouse mammary gland, loss of one Syk allele profoundly increases proliferation and ductal branching and invasion of epithelial cells through the mammary fat pad during puberty. Mammary carcinomas develop by one year. Syk also suppresses proliferation and invasion in vitro. siRNA or shRNA knockdown of Syk in MCF10A breast epithelial cells dramatically increased proliferation, anchorage independent growth, cellular motility, and invasion, with formation of functional, extracellular matrix-degrading invadopodia. Morphological and gene microarray analysis following Syk knockdown revealed a loss of luminal and differentiated epithelial features with epithelial to mesenchymal transition and a gain in invadopodial cell surface markers CD44, CD49F, and MMP14. These results support the role of Syk in limiting proliferation and invasion of epithelial cells during normal morphogenesis, and emphasize the critical role of Syk as a tumor suppressor for breast cancer. The question of breast cancer risk following systemic anti-Syk therapy is raised since only partial loss of Syk was sufficient to induce mammary carcinomas.
引用
收藏
页数:12
相关论文
共 47 条
[1]   Regulation of blood and lymphatic vascular separation by signaling proteins SLP-76 and Syk [J].
Abtahian, F ;
Guerriero, A ;
Sebzda, E ;
Lu, MM ;
Zhou, R ;
Mocsai, A ;
Myers, EE ;
Huang, B ;
Jackson, DG ;
Ferrari, VA ;
Tybulewicz, V ;
Lowell, CA ;
Lepore, JJ ;
Koretzky, GA ;
Kahn, ML .
SCIENCE, 2003, 299 (5604) :247-251
[2]   Adhesion structures and their cytoskeleton-membrane interactions at podosomes of osteoclasts in culture [J].
Akisaka, Toshitaka ;
Yoshida, Hisaho ;
Suzuki, Reiko ;
Takama, Keiko .
CELL AND TISSUE RESEARCH, 2008, 331 (03) :625-641
[3]   Dynamic interactions of cortactin and membrane type 1 matrix metalloproteinase at invadopodia: Defining the stages of invadopodia formation and function [J].
Artym, VV ;
Zhang, Y ;
Seillier-Moiseiwitsch, FO ;
Yamada, KM ;
Mueller, SC .
CANCER RESEARCH, 2006, 66 (06) :3034-3043
[4]  
Artym VV, 2009, METHOD MOL BIOL, V522, P1
[5]   Comparing the means and variances of a bivariate log-normal distribution [J].
Bebu, Ionut ;
Mathew, Thomas .
STATISTICS IN MEDICINE, 2008, 27 (14) :2684-2696
[6]   CONTROLLING THE FALSE DISCOVERY RATE - A PRACTICAL AND POWERFUL APPROACH TO MULTIPLE TESTING [J].
BENJAMINI, Y ;
HOCHBERG, Y .
JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES B-STATISTICAL METHODOLOGY, 1995, 57 (01) :289-300
[7]   Regulation of vimentin by SIP1 in human epithelial breast tumor cells [J].
Bindels, S. ;
Mestdagt, M. ;
Vandewalle, C. ;
Jacobs, N. ;
Volders, L. ;
Noel, A. ;
van Roy, F. ;
Berx, G. ;
Foidart, J-M ;
Gilles, C. .
ONCOGENE, 2006, 25 (36) :4975-4985
[8]   SYK TYROSINE KINASE REQUIRED FOR MOUSE VIABILITY AND B-CELL DEVELOPMENT [J].
CHENG, AM ;
ROWLEY, B ;
PAO, W ;
HAYDAY, A ;
BOLEN, JB ;
PAWSON, T .
NATURE, 1995, 378 (6554) :303-306
[9]   The Syk tyrosine kinase: A new negative regulator in tumor growth and progression [J].
Coopman, Peter J. ;
Mueller, Susette C. .
CANCER LETTERS, 2006, 241 (02) :159-173
[10]  
Coopman PJ, 1998, CLIN CANCER RES, V4, P507